Rethinking hypercortisolism screening in obesity and diabetes: A systematic review and meta-analysis.

MetabolismJun 14, 2026 (epub)
Clinical ResearchEndocrinology

Davide Ferrari, Ilaria Bonaventura, Marta Tenuta et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated hypercortisolism screening in individuals with obesity and diabetes. Among 14,995 participants, the prevalence of an abnormal dexamethasone suppression test (DST) was 4.6% in obesity and 14.3% in diabetes, with confirmed Cushing's syndrome at 0.8% and 2.1%, respectively. The study suggests a need to reassess screening strategies for these populations.

Key findings

  • In obesity, the prevalence of an abnormal DST was 4.6% (95%CI: 3.2-6.4).
  • In diabetes, 14.3% (95%CI: 10.9-18.4) had an abnormal DST, increasing to 23.3% after heterogeneity adjustment.
  • Confirmed Cushing's syndrome was found in 0.8% of obese and 2.1% of diabetic participants.
  • Age, recent weight gain, and diabetes were significant predictors of Cushing's syndrome.

Why it matters

Recognizing hypercortisolism in patients with obesity and diabetes is crucial, as it may be underdiagnosed. Improved screening could lead to better management of these patients and address potential secondary causes of their conditions.

Source

PubMed · PMID 42289244

Published in Metabolism. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Endocrinology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.